[go: up one dir, main page]

FR04C0018I2 - - Google Patents

Info

Publication number
FR04C0018I2
FR04C0018I2 FR04C0018C FR04C0018C FR04C0018I2 FR 04C0018 I2 FR04C0018 I2 FR 04C0018I2 FR 04C0018 C FR04C0018 C FR 04C0018C FR 04C0018 C FR04C0018 C FR 04C0018C FR 04C0018 I2 FR04C0018 I2 FR 04C0018I2
Authority
FR
France
Prior art keywords
antibody
medicament
administered
substantial
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR04C0018C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idec Pharmaceuticals Corp
Original Assignee
Idec Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25526490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR04C0018(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US1993/010953 external-priority patent/WO1994011026A2/fr
Application filed by Idec Pharmaceuticals Corp filed Critical Idec Pharmaceuticals Corp
Publication of FR04C0018I1 publication Critical patent/FR04C0018I1/fr
Application granted granted Critical
Publication of FR04C0018I2 publication Critical patent/FR04C0018I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FR04C0018C 1992-11-13 2004-07-15 Active FR04C0018I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97889192A 1992-11-13 1992-11-13
US08/149,099 US5736137A (en) 1992-11-13 1993-11-03 Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
PCT/US1993/010953 WO1994011026A2 (fr) 1992-11-13 1993-11-12 Application therapeutique d'anticorps chimeriques et radio-marques contre l'antigene a differentiation restreinte des lymphocytes b humains pour le traitement du lymphome des cellules b

Publications (2)

Publication Number Publication Date
FR04C0018I1 FR04C0018I1 (fr) 2008-09-26
FR04C0018I2 true FR04C0018I2 (fr) 2009-11-20

Family

ID=25526490

Family Applications (1)

Application Number Title Priority Date Filing Date
FR04C0018C Active FR04C0018I2 (fr) 1992-11-13 2004-07-15

Country Status (23)

Country Link
US (2) US5736137A (fr)
EP (1) EP2000149B1 (fr)
KR (1) KR100365632B1 (fr)
CN (5) CN1607006B (fr)
AT (2) ATE431158T1 (fr)
BR (1) BR1100622A (fr)
CA (1) CA2626445A1 (fr)
DE (3) DE69334259D1 (fr)
DK (2) DK2000149T3 (fr)
ES (2) ES2326144T3 (fr)
FR (1) FR04C0018I2 (fr)
GE (3) GEP20074162B (fr)
HU (1) HU219264B (fr)
IL (1) IL107591A (fr)
LU (1) LU91620I2 (fr)
MY (1) MY111196A (fr)
NL (1) NL300424I1 (fr)
PL (1) PL175557B1 (fr)
PT (2) PT2000149E (fr)
SG (1) SG45294A1 (fr)
TW (1) TW376320B (fr)
UA (1) UA27946C2 (fr)
ZA (1) ZA938466B (fr)

Families Citing this family (746)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US8771694B2 (en) * 1994-08-12 2014-07-08 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
ATE306930T1 (de) * 1994-08-12 2005-11-15 Immunomedics Inc Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US20030180290A1 (en) * 1995-06-07 2003-09-25 Idec Pharmaceuticals Corporation Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
US6373497B1 (en) 1999-05-14 2002-04-16 Zight Corporation Time sequential lookup table arrangement for a display
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7033589B1 (en) * 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6562950B2 (en) * 1997-09-02 2003-05-13 Insight Strategy & Marketing Ltd. Heparanase activity neutralizing anti-heparanase monoclonal antibody
US20010006630A1 (en) * 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
US20020088019A1 (en) * 1997-09-02 2002-07-04 Oron Yacoby-Zeevi Methods of and pharmaceutical compositions for improving implantation of embryos
US6699672B1 (en) * 1997-09-02 2004-03-02 Insight Biopharmaceuticals Ltd. Heparanase specific molecular probes and their use research and medical applications
US20040213789A1 (en) * 1997-09-02 2004-10-28 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
US20030161823A1 (en) * 1998-08-31 2003-08-28 Neta Ilan Therapeutic and cosmetic uses of heparanases
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
JP2002522511A (ja) * 1998-08-11 2002-07-23 アイデック ファーマスーティカルズ コーポレイション 抗ｃｄ２０抗体の投与を含むｂ細胞リンパ腫の併用療法
US20030217375A1 (en) * 1998-08-31 2003-11-20 Eyal Zcharia Transgenic animals expressing heparanase and uses thereof
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
ES2543819T3 (es) 1998-11-09 2015-08-24 Biogen Inc. Tratamiento de neoplasias hematológicas asociadas con células tumorales circulantes utilizando anticuerpo quimérico dirigido contra CD20
TR200101302T2 (tr) * 1998-11-09 2001-10-22 Idec Pharmaceuticals Corporation BMT yada PBSC transplantı alan hastalarda in vitro ya da in vivo temizleyici madde olarak kimerik anti-CD20 antikorunun kullanımı.
AU1727500A (en) * 1998-11-17 2000-06-05 Tanox, Inc. Bispecific molecules cross-linking itim and itam for therapy
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
BR0008758A (pt) * 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
EP1157118A4 (fr) * 1999-03-01 2002-07-17 Insight Strategy & Marketing Polynucleotide codant pour un polypeptide ayant une activite d'heparanase et expression de ce polynucleotide dans des cellules genetiquement modifiees
KR20020027311A (ko) * 1999-05-07 2002-04-13 제넨테크, 인크. Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료
EP1645290A1 (fr) 1999-05-07 2006-04-12 Genentech, Inc. Traitement de maladies auto-immunes au moyen d'antagonistes se liant aux marqueurs de surface de lymphocytes B
WO2000074718A1 (fr) * 1999-06-09 2000-12-14 Immunomedics, Inc. Immunotherapie de troubles auto-immuns a l'aide d'anticorps ciblant les cellules b
ITMI991299A1 (it) * 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
CA2383493C (fr) * 1999-06-25 2010-08-10 Genentech, Inc. Traitement du cancer de la prostate a l'aide des anticorps anti-erbb2
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
HK1047702A1 (zh) * 1999-07-12 2003-03-07 Genentech Inc. 用与cd20结合的拮抗剂阻断对外来抗原的免疫应答
US6451284B1 (en) * 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
AU6929100A (en) * 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
IL149500A0 (en) * 1999-11-08 2002-11-10 Idec Pharma Corp Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
WO2002004021A1 (fr) * 2000-07-12 2002-01-17 Idec Pharmaceuticals Corporation Traitement de malignites des cellules b au moyen d'une combinaison d'anticorps a action depletive sur les cellules b et des applications relatives a l'anticorps de modulation immunitaire
PT1255558E (pt) * 2000-02-16 2006-11-30 Genentech Inc Anticorpos anti-april e células hibridoma
US20030185796A1 (en) * 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
EP1283722A1 (fr) * 2000-03-31 2003-02-19 Idec Pharmaceuticals Corporation Utilisation combinee d'anticorps ou d'antagonistes anti-cytokine et d'anti-cd20 pour le traitement du lymphome b
DK1272647T3 (en) * 2000-04-11 2014-12-15 Genentech Inc Multivalent antibodies and uses thereof
AU5345901A (en) 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
MXPA02010507A (es) * 2000-04-25 2003-05-14 Idec Pharma Corp Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central.
EP1280923A2 (fr) * 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, un nouveau membre dans la famille de la trypsine humaine et son utilisation
IL152656A0 (en) * 2000-05-19 2003-06-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
CA2411102A1 (fr) 2000-06-20 2001-12-27 Idec Pharmaceutical Corporation Traitement de maladies associees aux cellules beta telles que les maladies auto-immunes a caractere malin par combinaison anticorps anti-cd20 froid/anticorps anti-cd22 radiomarque
CA2412901A1 (fr) * 2000-06-22 2001-12-27 Idec Pharmaceutical Corporation Proteine de fusion bispecifique et son procede d'utilisation permettant d'ameliorer l'action tueuse de cellules effectives sur des cellules cibles
US20060034830A1 (en) * 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US20060034828A1 (en) * 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
US20060024304A1 (en) * 2000-06-28 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
US20060029604A1 (en) * 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
CN1592645A (zh) * 2000-09-18 2005-03-09 拜奥根Idec公司 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
AU2002213357A1 (en) * 2000-10-20 2002-05-06 Idec Pharmaceuticals Corporation Variant igg3 rituxan r and therapeutic use thereof
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
NZ527591A (en) * 2001-01-17 2006-04-28 Trubion Pharmaceuticals Inc Binding domain-immunoglobulin fusion proteins
AU2008200400B2 (en) * 2001-01-17 2012-06-07 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
JP4463475B2 (ja) 2001-01-31 2010-05-19 バイオジェン アイデック インコーポレイテッド 腫瘍疾患の治療における免疫調節性抗体の使用
RU2306952C2 (ru) * 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
KR20080087184A (ko) 2001-01-31 2008-09-30 바이오겐 아이덱 인크. 종양질환 치료를 위한 ｃｄ23 길항제의 용도
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
JP2005500018A (ja) * 2001-04-02 2005-01-06 アイデック ファーマスーティカルズ コーポレイション ＧｎＴＩＩＩと同時発現する組換え抗体
WO2002078766A2 (fr) * 2001-04-02 2002-10-10 Genentech, Inc. Polytherapie
US20040136908A1 (en) * 2001-04-09 2004-07-15 Olson William C. Anti-cd19 immunotoxins
US20020193569A1 (en) * 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
CA2447791A1 (fr) * 2001-06-13 2002-12-19 Neslihan Delacruz Procedes de mise en culture de cellules animales et production de polypeptides dans des cellules animales
CA2455365C (fr) * 2001-08-03 2014-07-29 Glycart Biotechnology Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
KR20040019105A (ko) * 2001-08-03 2004-03-04 제넨테크, 인크. ＴＡＣＩｓ 및 ＢＲ3 폴리펩티드 및 이의 용도
AU2002326581A1 (en) * 2001-08-10 2003-03-03 University Of Virginia Patent Foundation Enhancing the efficacy of immunotherapies by supplementing with complement
US7214428B2 (en) * 2001-09-17 2007-05-08 Invitrogen Corporation Highly luminescent functionalized semiconductor nanocrystals for biological and physical applications
DE60234382D1 (de) 2001-09-17 2009-12-24 Life Technologies Corp Nanokristalle
US7205048B2 (en) * 2001-09-17 2007-04-17 Invitrogen Corporation Functionalized fluorescent nanocrystal compositions and methods of making
JP4424987B2 (ja) * 2001-09-20 2010-03-03 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Ｅｌｉｓａアッセイを用いた循環する治療抗体、抗原および抗原／抗体複合体の測定
ES2561985T3 (es) 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
US20050069962A1 (en) 2001-10-12 2005-03-31 Archer Robert M Antibody complexes and methods for immunolabeling
US8323903B2 (en) * 2001-10-12 2012-12-04 Life Technologies Corporation Antibody complexes and methods for immunolabeling
US7858300B2 (en) * 2001-10-19 2010-12-28 Centre Hospitalier Regional Et Universitaire De Tours Methods and compositions to evaluate antibody treatment response
ATE430580T1 (de) * 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US6671189B2 (en) * 2001-11-09 2003-12-30 Minebea Co., Ltd. Power converter having primary and secondary side switches
EP2022799A2 (fr) 2001-11-16 2009-02-11 Biogen Idec Inc. Expression polycistronique d'anti-corps
US20060024292A1 (en) * 2001-12-27 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
JP4460302B2 (ja) 2002-02-05 2010-05-12 ジェネンテック インコーポレイテッド タンパク質精製法
EP2034009B1 (fr) 2002-02-08 2014-01-15 Life Technologies Corporation Compositions et procedes de restauration de reponse immunitaire chez des patients souffrant de deficiences immunologiques basant sur cd3/cd28 costimulation
US8287864B2 (en) * 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
CN100522999C (zh) * 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2003074567A2 (fr) * 2002-03-01 2003-09-12 Immunomedics, Inc. Internalisation d'anticorps anti-cd74 et methodes d'utilisation correspondantes
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090042291A1 (en) * 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US8361464B2 (en) 2002-03-01 2013-01-29 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
JP4319979B2 (ja) 2002-04-26 2009-08-26 ジェネンテック・インコーポレーテッド タンパク質の非アフィニティ精製
AU2003256836A1 (en) * 2002-07-25 2004-02-16 Genentech, Inc. Taci antibodies and uses thereof
US8193318B2 (en) * 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) * 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) * 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
CA2499816C (fr) 2002-09-27 2013-07-30 Xencor, Inc. Variants fc optimises et methodes destinees a leur generation
WO2004035607A2 (fr) * 2002-10-17 2004-04-29 Genmab A/S Anticorps monoclonaux humains anti-cd20
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
CA2506320A1 (fr) * 2002-11-21 2004-06-10 Genentech, Inc. Therapie de maladies ou troubles benins a l'aide d'anticorps anti-erbb2
SE0203731D0 (sv) * 2002-12-13 2002-12-13 Mitra Medical Technology Ab Reagent
PT1572744E (pt) * 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
US7960512B2 (en) * 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1587540B1 (fr) * 2003-01-09 2021-09-15 MacroGenics, Inc. Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
JP4177123B2 (ja) * 2003-01-10 2008-11-05 富士通株式会社 配線図形検証方法、プログラム及び装置
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
EA200501197A1 (ru) * 2003-01-27 2006-04-28 Байоджен Айдек Ма Инк. Композиции и способы для лечения злокачественной опухоли с применением igsf9 и liv - 1
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
HRP20090325T1 (en) * 2003-04-09 2009-07-31 Genentech Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
NZ543960A (en) * 2003-05-09 2008-11-28 Univ Duke CD20-specific antibodies and methods of employing same
EP2272868B1 (fr) 2003-06-05 2015-03-04 Genentech, Inc. Thérapie de combinaison pour des désordres de cellules B
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
WO2004108065A2 (fr) * 2003-06-09 2004-12-16 Insight Biopharmaceuticals Ltd. Activite d'heparanase neutralisant un anticorps monoclonal anti-heparanase et d'autres anticorps anti-heparanase
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
PL3095793T3 (pl) 2003-07-28 2020-09-07 Genentech, Inc. Redukcja wycieku białka A w trakcie chromatografii powinowactwa z białkiem A
CN1860367B (zh) * 2003-07-29 2010-05-26 健泰科生物技术公司 人抗cd20抗体的测定法及其用途
ZA200601218B (en) * 2003-08-29 2007-05-30 Genentech Inc Anti-CD20 therapy of ocular disorders
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
KR101229731B1 (ko) 2003-10-16 2013-03-07 암젠 리서치 (뮌헨) 게엠베하 다중특이적 탈면역화된 ｃｄ3-바인더
PT1684869E (pt) 2003-11-04 2011-09-16 Novartis Vaccines & Diagnostic Métodos de terapêutica para cancros relacionados com células b
EP1682179A4 (fr) * 2003-11-05 2008-09-03 Palingen Inc Cytotoxicite augmentee de l'anticorps de liaison cdim contre les lymphocytes b
ME01775B (fr) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Molecules fixatrices d'antigenes presentant une affinite de fixation du recepteur de fc et une fonction effectrice accrues
CA2545603A1 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
US7750123B2 (en) * 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof
CN1918181A (zh) * 2003-12-19 2007-02-21 健泰科生物技术公司 移植排斥中cd20的检测
CA2549122A1 (fr) * 2003-12-19 2005-07-07 Genentech, Inc. Detection cd20 pour traitement des maladies auto-immunes
FR2867982B1 (fr) * 2004-03-26 2007-07-20 Jean Marie Andrieu Procede pour amplifier l'activite de vaccins therapeutiques
JP2007532681A (ja) * 2004-04-16 2007-11-15 ジェネンテック・インコーポレーテッド Ｂ細胞の枯渇を増大させる方法
WO2005108989A2 (fr) * 2004-04-16 2005-11-17 Genentech, Inc. Dosage pour anticorps
WO2005115453A2 (fr) * 2004-04-16 2005-12-08 Genentech, Inc. Traitement de troubles
EP1740946B1 (fr) * 2004-04-20 2013-11-06 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
BRPI0510224A (pt) * 2004-05-05 2007-10-23 Genentech Inc métodos de prevenção de doença autoimunológica e artigo industrializado
CN103127502A (zh) 2004-05-20 2013-06-05 津莫吉尼蒂克斯公司 使用il-21和单克隆抗体疗法治疗癌症的方法
EP1753455A2 (fr) 2004-06-04 2007-02-21 Genentech, Inc. Methode de traitement de la sclerose en plaques
AU2005251764A1 (en) * 2004-06-04 2005-12-22 Genentech, Inc. Method for treating lupus
US9109255B2 (en) * 2004-06-18 2015-08-18 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining responsiveness to antibody therapy
BRPI0510674A (pt) 2004-07-15 2007-12-26 Xencor Inc variantes fc otimizadas
US20060062787A1 (en) * 2004-07-22 2006-03-23 Genentech, Inc. Method for treating Sjogren's syndrome
CN101048427B (zh) 2004-07-23 2015-01-14 健泰科生物技术公司 抗体或其片段的结晶
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
JP2008510852A (ja) * 2004-08-17 2008-04-10 インヴィトロジェン コーポレーション 高発光性コロイド粒子の合成
WO2006031370A2 (fr) * 2004-08-19 2006-03-23 Genentech, Inc. Variants de polypeptides dotes d'une fonction effectrice modifiee
BRPI0515589A (pt) * 2004-09-02 2008-07-29 Genentech Inc polipeptìdeos ou anticorpos de ligação de antìgeno isolado, anticorpo isolado, método para regular de forma negativa a atividade de fc(gama)riib, métodos de tratamento, anticorpos biespecìficos isolados, métodos de inibição de uma resposta imune, de supressão na liberação de histamina, de ativação de fc(gama)riib, de inibição da expressão do receptor fc(épsilon)ri, composição e kit
US7655229B2 (en) * 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) * 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
NZ553174A (en) * 2004-09-08 2010-03-26 Genentech Inc Methods of using death receptor ligands Apo2L/Trail and CD20 antibodies
JP2008512479A (ja) * 2004-09-08 2008-04-24 ジェネンテック・インコーポレーテッド デスレセプターリガンド及びｃｄ２０抗体の使用方法
SG165344A1 (en) * 2004-10-05 2010-10-28 Genentech Inc Method for treating vasculitis
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2305775A3 (fr) 2004-10-29 2011-06-08 Molecular Probes, Inc. Nanocristaux fluorescents fonctionnalisés et procédés pour leur préparation et utilisation
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
GB2420976B (en) * 2004-11-19 2006-12-20 Zvi Finkelstein Therapeutic implant
SG158089A1 (en) * 2004-12-17 2010-01-29 Genentech Inc Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
SG176509A1 (en) 2004-12-22 2011-12-29 Genentech Inc Methods for producing soluble multi-membrane-spanning proteins
EP1674479A1 (fr) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation des récepteurs Fc gamma pour optimiser l'immunothérapie
BRPI0519354B8 (pt) * 2004-12-23 2021-07-27 Hoffmann La Roche método para detecção de um anticorpo terapêutico e uso de um anticorpo
DE602004021404D1 (de) 2004-12-23 2009-07-16 Gpc Biotech Ag Quadratsäurederivate mit antiproliferativer Wirkung
EP2311880A3 (fr) 2005-01-05 2011-07-27 Biogen Idec MA Inc. Molécules à crypto-liaison
WO2006076651A2 (fr) * 2005-01-13 2006-07-20 Genentech, Inc. Procede de traitement
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
AU2006236439B2 (en) 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2012018687A1 (fr) 2010-08-02 2012-02-09 Macrogenics, Inc. Di-anticorps covalents et utilisations associées
CA2607475A1 (fr) * 2005-04-22 2006-11-02 Genentech, Inc. Methode pour traiter la demence ou la maladie d'alzheimer
WO2006117782A2 (fr) * 2005-05-04 2006-11-09 Quark Pharmaceuticals, Inc. Anticorps recombinants diriges contre cd55 et cd59 et leur utilisation
MX2007013924A (es) * 2005-05-09 2008-01-28 Glycart Biotechnology Ag Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc.
CN1865275B (zh) * 2005-05-17 2011-06-15 长春华普生物技术有限公司 对人b细胞肿瘤有治疗作用的人工合成的单链脱氧核苷酸
CN101223448B (zh) * 2005-05-20 2012-01-18 健泰科生物技术公司 来自自身免疫病受试者的生物学样品的预处理
AP2007004252A0 (en) * 2005-05-24 2007-12-31 Avestha Gengraine Tech Pvt Ltd A method for the production of a monoclonal antibody to cd20 for the treatment of B-cell lymphoma
WO2007008547A2 (fr) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Anticorps anti-sp35 et leurs utilisations
HUE026303T2 (hu) 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
BRPI0614183A2 (pt) 2005-07-25 2011-03-15 Trubion Pharmaceuticals Inc uso de dose única de moléculas de ligação especìficas para cd20
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
PL1919503T3 (pl) 2005-08-10 2015-04-30 Macrogenics Inc Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500353A3 (fr) 2005-08-19 2012-10-10 Abbott Laboratories Immunoglobuline à double domaine variable et ses utilisations
TWI323734B (en) 2005-08-19 2010-04-21 Abbott Lab Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
JP2009507040A (ja) * 2005-09-02 2009-02-19 グライコフィ， インコーポレイテッド 主としてｇｌｃｎａｃｍａｎ３ｇｌｃｎａｃ２糖形態を含む免疫グロブリン
US20070161089A1 (en) * 2005-11-08 2007-07-12 Genentech, Inc. Method of Producing Pan-Specific Antibodies
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2629306A1 (fr) 2005-11-23 2007-05-31 Genentech, Inc. Procedes et compositions lies a des analyses de lymphocytes b
US20070136826A1 (en) * 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
JPWO2007102200A1 (ja) * 2006-03-07 2009-07-23 国立大学法人大阪大学 抗ｃｄ２０モノクローナル抗体
JP2009529331A (ja) * 2006-03-10 2009-08-20 マクロジェニクス，インコーポレーテッド 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
MX2008012013A (es) 2006-03-23 2008-10-03 Novartis Ag Tratamiento con anticuerpo antigeno de celulas neoplasicas.
EP3026123A1 (fr) 2006-04-27 2016-06-01 Klaritos, Inc. Procédé et trousses pour predire la thérapie par anticorps
US20080118978A1 (en) 2006-04-28 2008-05-22 Takashi Sato Anti-tumor agent
US7727525B2 (en) * 2006-05-11 2010-06-01 City Of Hope Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
CA2660592C (fr) 2006-05-26 2016-07-12 Macrogenics, Inc. Anticorps specifiques fcgriib humanises, et leurs procedes d'utilisation
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
CA2656224C (fr) 2006-06-26 2018-01-09 Macrogenics, Inc. Association d'anticorps anti-fc.gamma.riib et d'anticorps anti-cd20, et methodes d'utilisation
EP2505209A1 (fr) * 2006-06-26 2012-10-03 MacroGenics, Inc. Anticorps spécifiques au FcgammaRIIB et procédés d'utilisation associés
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8636995B2 (en) * 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
US8372399B2 (en) * 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US20080058922A1 (en) * 2006-08-31 2008-03-06 Cardiac Pacemakers, Inc. Methods and devices employing vap-1 inhibitors
US20080112961A1 (en) * 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
US8652466B2 (en) * 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
US8163886B2 (en) * 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8906367B2 (en) 2007-01-05 2014-12-09 University Of Zurich Method of providing disease-specific binding molecules and targets
NO2740744T3 (fr) 2007-01-09 2018-08-25
DE102007001370A1 (de) * 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
JP5361738B2 (ja) 2007-01-22 2013-12-04 ジェネンテック， インコーポレイテッド 多価電解質沈殿物及びタンパク質の精製
US8450348B2 (en) * 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
RU2009137582A (ru) 2007-03-12 2011-04-20 Эсбатек Аг (Ch) Инженерия и оптимизация одноцепочечных антител на основе последовательности
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2008122039A2 (fr) * 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molécules d'anticorps hybrides médiées par la sélénocystéine
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
EP1995309A1 (fr) * 2007-05-21 2008-11-26 Vivalis Production de protéine recombinante dans des cellules aviaires EBx
EP2019101A1 (fr) * 2007-07-26 2009-01-28 GPC Biotech AG Pyrazol[3,4-d]pyrimidin-4-one utile en tant que Inhibiteur de kinase
BRPI0813645A2 (pt) * 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
EP2164961B1 (fr) * 2007-06-25 2015-01-07 ESBATech, an Alcon Biomedical Research Unit LLC Ingénierie basée sur les séquences et optimisation d'anticorps monocaténaires
US20090324596A1 (en) 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
WO2009009523A2 (fr) 2007-07-09 2009-01-15 Genentech, Inc. Prévention de la réduction des liaisons disulfure au cours de la production recombinante de polypeptides
WO2009018411A1 (fr) * 2007-07-31 2009-02-05 Regeneron Pharmaceuticals, Inc. Anticorps humains en cd20 humain et leur procédé d'utilisation
JP5209723B2 (ja) 2007-09-05 2013-06-12 エフ．ホフマン−ラ ロシュ アーゲー Ｉ型及びｉｉ型抗ｃｄ２０抗体による組合せ治療
WO2009045370A2 (fr) 2007-09-28 2009-04-09 Intrexon Corporation Constructions et bioréacteurs de commutation de gène théapeutique destinés à l'expression de molécules biothérapeutiques, et utilisation de ceux-ci
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
WO2009052293A1 (fr) 2007-10-16 2009-04-23 Zymogenetics, Inc. Combinaison d'agents d'inhibition de blys et d'agents anti-cd 20 pour le traitement d'une maladie auto-immune
JP2011500608A (ja) * 2007-10-22 2011-01-06 オンコリティクス バイオテク，インコーポレーテッド 増殖性障害の治療レジメン
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
CL2008003218A1 (es) 2007-10-30 2009-03-06 Genentech Inc Método para la purificación de un anticuerpo a partir de una composición que comprende el anticuerpo y al menos un contaminante.
US8795667B2 (en) * 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
CA2707791A1 (fr) * 2007-12-21 2009-07-09 Genentech, Inc. Therapie de patients atteints d'arthrite rhumatoide refractaires au rituximab
ES2742268T3 (es) 2007-12-26 2020-02-13 Xencor Inc Variantes de Fc con unión alterada a FcRn
EP2077281A1 (fr) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anticorps anti-CD20 ou fragments correspondants pour le traitement de syndrome de fatigue chronique
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2085095B1 (fr) 2008-01-17 2012-03-07 Philogen S.p.A. Combinaison de protéine de fusion anticorps de fibronectine anti-EDb-IL-2, et molécule se liant aux lymphocytes B, progéniteurs de lymphocytes B et/ou leur contrepartie cancéreuse
MX2010007767A (es) 2008-01-18 2010-08-09 Medimmune Llc Anticuerpos manipulados con cisteina para conjugacion especifica de sitio.
WO2009097095A2 (fr) * 2008-01-28 2009-08-06 The Regents Of The University Of California Procédés de traitement des tumeurs malignes
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
ES2592312T3 (es) * 2008-03-25 2016-11-29 Roche Glycart Ag Utilización de un anticuerpo anti-CD20 de tipo II con citotoxicidad celular dependiente de anticuerpos (ADCC) incrementada en combinación con ciclofosfamida, vincristina y doxorrubicina para el tratamiento de linfomas no de Hodgkin
JP5785490B2 (ja) 2008-04-02 2015-09-30 マクロジェニクス，インコーポレーテッド Ｂｃｒ複合体特異的抗体およびその使用方法
SG189730A1 (en) 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
AU2009234277B2 (en) * 2008-04-11 2014-12-04 Aptevo Research And Development Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2112150B1 (fr) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Inhibiteurs Raf améliorés
EP2112152A1 (fr) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones comme inhibiteurs Plk
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CN102076355B (zh) 2008-04-29 2014-05-07 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US20090269339A1 (en) * 2008-04-29 2009-10-29 Genentech, Inc. Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
AU2009256246B2 (en) * 2008-06-03 2013-07-18 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
ES2675730T3 (es) * 2008-06-04 2018-07-12 Macrogenics, Inc. Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
WO2009151514A1 (fr) * 2008-06-11 2009-12-17 Millipore Corporation Bioréacteur à cuve agitée
CA2728829C (fr) 2008-06-25 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Optimisation de solubilite d'agents de liaison immunologique
EP2310006A4 (fr) 2008-07-03 2012-04-25 Mayo Foundation Traitement du cancer
KR101054362B1 (ko) 2008-07-03 2011-08-05 재단법인 목암생명공학연구소 재조합 단백질의 푸코스 함량을 감소시키는 방법
AU2009268585C1 (en) * 2008-07-08 2014-10-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
JP2011527572A (ja) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｎｇｏ抗体または断片を含む組成物
KR101030978B1 (ko) * 2008-07-10 2011-04-28 (주) 에이프로젠 동물세포용 재조합 발현벡터
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
AR077718A1 (es) * 2008-07-15 2011-09-21 Genentech Inc Metodos para tratar enfermedades autoinmunes usando anticuerpos anti cd4. formulacion farmaceutica
EP2318048B1 (fr) * 2008-07-21 2019-05-29 Immunomedics, Inc. Variants structuraux d'anticorps pour obtenir de meilleures caractéristiques thérapeutiques
US8900851B2 (en) * 2008-07-22 2014-12-02 The Research Foundation For The State University Of New York Multi-well platform
KR101843915B1 (ko) 2008-08-14 2018-04-02 제넨테크, 인크. 고유 단백질 대체 이온 교환 막 크로마토그래피를 이용한 오염물의 제거 방법
WO2010030670A2 (fr) 2008-09-10 2010-03-18 Genentech, Inc. Compositions et procédés permettant d’éviter la dégradation oxydative des protéines
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
AU2009309387A1 (en) * 2008-10-28 2010-05-06 Avesthagen Limited An expression vector and processes thereof
SG171812A1 (en) * 2008-12-04 2011-07-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
GB2466025A (en) 2008-12-08 2010-06-09 Univ Francois Rabelais De Tour C3/ITGAM polymorphisms and cancer prognosis
WO2010068722A1 (fr) 2008-12-12 2010-06-17 Medimmune, Llc Cristaux et structure d'un variant de fc d'igg humain avec liaison augmentée à fcrn
ES2749232T3 (es) 2008-12-16 2020-03-19 Emd Millipore Corp Reactor de tanque agitado y procedimiento
CN102256993A (zh) * 2008-12-16 2011-11-23 米利波尔公司 蛋白的纯化
WO2010069603A1 (fr) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Auto-anticorps humains anti-alpha-synucléine
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
WO2010074724A1 (fr) 2008-12-22 2010-07-01 Millennium Pharmaceuticals, Inc. Inhibiteurs d'aurora kinases associés avec des anticorps anti-cd20
JP2012514458A (ja) 2008-12-31 2012-06-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗リンホトキシン抗体
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
JP5828151B6 (ja) 2009-01-06 2018-09-19 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル アテローム性動脈硬化の処置のためのｂ細胞枯渇剤
EP2400992B1 (fr) 2009-02-27 2015-07-22 Genentech, Inc. Procédés et compositions pour le marquage des protéines
PE20160653A1 (es) 2009-03-05 2016-07-24 Abbvie Inc Proteinas de union a il-17
HRP20161194T1 (hr) 2009-03-10 2016-11-04 Biogen Ma Inc. Anti-bcma protutijela
CA2753285A1 (fr) 2009-03-12 2010-09-16 Genentech, Inc. Combinaisons de composes inhibiteurs de phosphoinositide 3-kinase et d'agents chimiotherapeutiques pour le traitement de tumeurs malignes hematopoietiques
EP2233500A1 (fr) 2009-03-20 2010-09-29 LFB Biotechnologies Variantes Fc optimisées
JP2012521216A (ja) 2009-03-24 2012-09-13 テバ バイオファーマスーティカルズ ユーエスエー，インコーポレーテッド Ｌｉｇｈｔに対するヒト化抗体およびその使用
AR075982A1 (es) 2009-03-31 2011-05-11 Roche Glycart Ag Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
EP2435476A4 (fr) 2009-05-27 2013-04-17 Synageva Biopharma Corp Anticorps d'origine aviaire
WO2010145846A1 (fr) 2009-06-15 2010-12-23 Bayer Bioscience N.V. Plants de nicotinia benthamiana à activité xylosyltransférase déficiente
US20120213705A1 (en) 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
WO2011000543A1 (fr) * 2009-06-30 2011-01-06 Philochem Ag Banque de présentation d’anticorps murin
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
SI2464725T2 (sl) 2009-08-11 2025-06-30 F. Hoffmann-La Roche Ag Proizvodnja beljakovin v medijih za celične kulture brez glutamina
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
AR077867A1 (es) 2009-08-14 2011-09-28 Roche Glycart Ag Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona
CA2772653C (fr) 2009-09-01 2019-06-25 Genentech, Inc. Purification amelioree d'une proteine grace a une elution modifiee de la proteine a
TW201119673A (en) 2009-09-01 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
MX353186B (es) * 2009-09-03 2018-01-05 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
KR101808602B1 (ko) 2009-10-07 2017-12-13 마크로제닉스, 인크. 푸코실화 정도의 변경으로 인해 개선된 이펙터 기능을 나타내는 Ｆｃ 영역-함유 폴리펩티드, 그것의 사용 방법
UY32948A (es) 2009-10-15 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
BR112012005668A2 (pt) * 2009-10-19 2020-10-13 F. Hoffmann La Roche Ag '' linhagem celular, anticorpo, uso de um anticorpo, kit, método de detecção de um anticorpo terapêutico, método de determinação imunológica de um anticorpo terapêutico, composição de anticorpo, uso de uma composição de anticorpo''
EP2325185A1 (fr) 2009-10-28 2011-05-25 GPC Biotech AG Inhibiteur de Plk
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
US20120309056A1 (en) 2010-02-04 2012-12-06 Leon Arnaud Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
WO2011097527A2 (fr) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection de fractions thérapeutiques avec des régions fc améliorées
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
US9175086B2 (en) * 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
CN102782131B (zh) 2010-03-02 2015-08-05 协和发酵麒麟株式会社 修饰抗体组合物
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
KR102218495B1 (ko) 2010-03-22 2021-02-19 제넨테크, 인크. 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
ES2621874T3 (es) 2010-03-26 2017-07-05 Memorial Sloan-Kettering Cancer Center Anticuerpos para MUC16 y métodos de uso de los mismos
JP5767207B2 (ja) 2010-03-26 2015-08-19 協和発酵キリン株式会社 新規修飾部位導入抗体および抗体フラグメント
RU2012145183A (ru) 2010-03-29 2014-05-10 Займворкс, Инк. Антитела с повышенной или пониженной эффекторной функцией
EP4450523A3 (fr) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Protéines de fusion de liaison, conjugués protéine de fusion-médicament de liaison, conjugués xten-médicament et leurs procédés de fabrication et d'utilisation
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
RU2585489C2 (ru) 2010-04-27 2016-05-27 Рош Гликарт Аг КОМБИНИРОВАННАЯ ТЕРАПИЯ АФУКОЗИЛИРОВАННЫМ АНТИТЕЛОМ CD20 И ИНГИБИТОРОМ mTOR
JP2013525484A (ja) 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
AU2011250970B2 (en) 2010-05-10 2016-12-15 Sinica, Academia Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
EP2571532B1 (fr) 2010-05-14 2017-05-03 Abbvie Inc. Protéines liant l'il-1
SG10201804385YA (en) 2010-05-17 2018-06-28 Emd Millipore Corp Stimulus responsive polymers for the purification of biomolecules
MY161534A (en) 2010-05-25 2017-04-28 Genentech Inc Methods of purifying polypeptides
RU2614125C2 (ru) 2010-05-28 2017-03-22 Дженентек, Инк. Снижение уровня лактата и увеличение продукции полипептида путем ингибирования экспрессии лактатдегидрогеназы и киназы пируватдегидрогеназы
MY161390A (en) 2010-06-24 2017-04-14 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012006635A1 (fr) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Molécules à chaîne unique pouvant être traitées et polypeptides faits à partir de celles-ci
EP2409712A1 (fr) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anticorps Anti-CD19 doté de fonctions ADCC et CDC et d'un profil de glycosylation amélioré
EP2409993A1 (fr) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anticorps Anti-CD19 doté d'une fonction ADCC et d'un profil de glycosylation amélioré
CA2806252C (fr) 2010-07-29 2019-05-14 Xencor, Inc. Anticorps dont les points isoelectriques sont modifies
US20130130317A1 (en) 2010-08-02 2013-05-23 Kyowa Hakko Kirin Co., Ltd Method for producing substance
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
MX2013001302A (es) 2010-08-03 2013-03-08 Hoffmann La Roche Biomarcadores de leucemia linfocitica (cll).
CA2807552A1 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucleiques modifies et leurs procedes d'utilisation
RU2013110844A (ru) 2010-08-13 2014-09-20 Дженентек, Инк. АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
RU2603284C2 (ru) * 2010-08-17 2016-11-27 Ф.Хоффманн-Ля Рош Аг АНТИТЕЛА ПРОТИВ IgG1 ЧЕЛОВЕКА
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
WO2012030512A1 (fr) 2010-09-03 2012-03-08 Percivia Llc. Procédé de purification de protéine en flux
EP3431485B2 (fr) 2010-10-01 2024-09-04 ModernaTX, Inc. Acides nucléiques techniques et leurs procédés d'utilisation
LT2627672T (lt) 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
EP4029881A1 (fr) 2010-11-08 2022-07-20 F. Hoffmann-La Roche AG Anticorps du récepteur anti-il-6 administré par voie sous-cutanée
KR102058658B1 (ko) 2010-12-15 2019-12-24 다이가쿠쿄도리요우키칸호우진 죠우호우시스테무 겡큐키코우 단백질의 생산 방법
RU2013131444A (ru) 2010-12-16 2015-01-27 Рош Гликарт Аг Сочетанная терапия афукозилированным антителом к cd20 и ингибитором mdm2
CN103380145B (zh) 2010-12-17 2016-10-12 生物控股有限公司 人类抗-sod1抗体
MY163368A (en) 2010-12-21 2017-09-15 Abbvie Inc Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
US9611458B2 (en) 2010-12-27 2017-04-04 Kyowa Hakko Kirin Co., Ltd Method for preparing aqueous solution containing culture medium and chelating agent
WO2012095514A1 (fr) 2011-01-14 2012-07-19 Vivalis Système de production de protéines recombinantes
WO2012106368A2 (fr) 2011-01-31 2012-08-09 The Regents Of The University Of California Procédés d'inhibition du cancer de la prostate
CN103502472B (zh) 2011-02-28 2017-06-06 弗·哈夫曼-拉罗切有限公司 生物标记物和用于预测对b‑细胞拮抗剂的响应的方法
TWI803876B (zh) 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
KR20160044598A (ko) 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
WO2012135805A2 (fr) 2011-03-31 2012-10-04 modeRNA Therapeutics Administration et formulation d'acides nucléiques génétiquement modifiés
EP2506015A1 (fr) 2011-04-01 2012-10-03 Universität Regensburg Signature pronostique et thérapeutique pour le mélanome malin
CA3019531A1 (fr) 2011-04-19 2012-10-26 Pfizer Inc. Combinaisons d'anticorps anti-4-1bb et d'anticorps induisant une cytotoxicite a mediation cellulaire dependante d'un anticorps (adcc) pour le traitement du cancer
WO2012154861A2 (fr) 2011-05-09 2012-11-15 Mayo Foundation For Medical Education And Research Traitements du cancer
CA2833212C (fr) 2011-05-12 2020-06-09 Genentech, Inc. Reaction multiple de surveillance du procede lc-ms/ms pour detecter les anticorps therapeutiques dans les echantillons d'animaux par des peptides de signature du cadre
EP2710042A2 (fr) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Protéines de fusion contenant un fab multi-spécifique et procédé d'utilisation
ME03440B (fr) 2011-05-21 2020-01-20 Macrogenics Inc Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
WO2012162068A2 (fr) 2011-05-21 2012-11-29 Macrogenics, Inc. Domaines de liaison du sérum déimmunisé et leur utilisation pour prolonger la demi-vie du sérum
RU2011122942A (ru) 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Новые ингибиторы киназ
LT2723379T (lt) 2011-06-23 2018-10-25 Biogen International Neuroscience Gmbh Anti-alfa sinukleiną rišančios molekulės
EP2537933A1 (fr) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Immunocytokines basées sur le domaine IL-15 et IL-15Ralpha sushi
US20140234298A1 (en) 2011-07-06 2014-08-21 Morphosys Ag Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
KR101902225B1 (ko) 2011-07-08 2018-09-28 이엠디 밀리포어 코포레이션 일회용 생명공학적 공정용의 개선된 심층 필터
WO2019071023A1 (fr) 2017-10-04 2019-04-11 Yale University Compositions et procédés de fabrication de polypeptides contenant de la sélénocystéine
US9464288B2 (en) 2011-07-11 2016-10-11 Yale University Compositions and methods for making selenocysteine containing polypeptides
WO2013012733A1 (fr) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Régions fc hétérodimères, molécules de liaison les comprenant, et méthodes associées
EP2550975A1 (fr) 2011-07-29 2013-01-30 Sanofi Polythérapie pour le traitement de symptômes de malignités CD19+lymphocytes B comprenant un immunoconjugué anti-CD19 maytansinoïde et du rituximab
EP2551348B1 (fr) 2011-07-29 2014-09-24 Icon Genetics GmbH Production de N-glycanes galactosylatées dans des plantes
WO2013022855A1 (fr) 2011-08-05 2013-02-14 Xencor, Inc. Anticorps avec points isoélectriques modifiés et immunofiltration
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013049362A2 (fr) 2011-09-27 2013-04-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Méthode de traitement de la sclérose en plaques par la déplétion intrathécale de lymphocytes b et biomarqueurs pour choisir des patients atteints d'une sclérose en plaques progressive
EP2763701B1 (fr) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Nucléosides, nucléotides et acides nucléiques modifiés, et leurs utilisations
WO2013050155A1 (fr) 2011-10-04 2013-04-11 Icon Genetics Gmbh Plantes nicotiana benthamiana déficientes dans l'activité fucosyltransférase
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CA2851534C (fr) 2011-10-10 2023-02-14 Xencor, Inc. Procede de purification d'anticorps
JP2014533659A (ja) 2011-10-24 2014-12-15 アッヴィ・インコーポレイテッド スクレロスチンに対するイムノバインダー
US9790280B2 (en) 2011-10-26 2017-10-17 Elanco Tiergesundheit Ag Monoclonal canine CD20 antibodies and methods of use
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
IL267585B (en) 2011-12-22 2022-09-01 Genentech Inc Ion exchange membrane chromatography
WO2013102042A2 (fr) 2011-12-30 2013-07-04 Abbvie Inc. Protéines à double liaison spécifique dirigées contre l'il-13 et/ou l'il-17
JP2015506950A (ja) 2012-01-31 2015-03-05 ジェネンテック， インコーポレイテッド 抗ｉｇ−ｅｍ１’抗体およびそれを用いる方法
JP6170077B2 (ja) 2012-02-16 2017-07-26 エータイアー ファーマ， インコーポレイテッド 自己免疫および炎症疾患を処置するためのヒスチジルｔＲＮＡ合成酵素
SG11201406112TA (en) 2012-03-27 2014-10-30 Genentech Inc Improved harvest operations for recombinant proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
JP2015518829A (ja) 2012-05-14 2015-07-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 運動ニューロンに関する状態の処置のためのｌｉｎｇｏ−２アンタゴニスト
SG11201408161RA (en) 2012-06-08 2015-01-29 Sutro Biopharma Inc Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
WO2014011955A2 (fr) 2012-07-12 2014-01-16 Abbvie, Inc. Protéines de liaison à il-1
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
EP2885311B1 (fr) 2012-08-18 2020-01-01 Academia Sinica Sondes perméables aux cellules pour l'identification et l'imagerie de sialidases
CA2883168A1 (fr) 2012-08-21 2014-02-27 Academia Sinica Composes benzocyclo-octyne et leurs utilisations
ES2728864T3 (es) 2012-08-31 2019-10-29 Sutro Biopharma Inc Aminoácidos modificados que comprenden un grupo azido
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US9777067B2 (en) 2012-09-27 2017-10-03 Massachusetts Institute Of Technology HER2- and VEGF-A-binding proteins with enhanced stability
EP2903610B1 (fr) 2012-10-01 2021-11-03 Mayo Foundation For Medical Education And Research Traitements antinéoplasiques
HK1213794A1 (zh) 2012-10-09 2016-07-15 Biogen Ma Inc. 联合治疗及用於治疗脱髓鞘病症的用途
HUE045435T2 (hu) 2012-10-12 2019-12-30 Medimmune Ltd Pirrolobenzodiazepinek és konjugátumaik
HK1212359A1 (en) 2012-11-01 2016-06-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
BR112015009924A2 (pt) 2012-11-01 2017-12-05 Abbvie Inc formulações de proteína imunoglobulina de domínio variável duplo estáveis
KR102341275B1 (ko) 2012-11-02 2021-12-21 티지 쎄라퓨틱스, 인코포레이티드 항cd20 항체와 pi3 키나아제 선택적 억제제의 조합물
CA2892529C (fr) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Arn modifie a son extremite terminale
EP2934602B1 (fr) 2012-12-19 2019-02-27 Genentech, Inc. Procédés et compositions pour le marquage de protéines par un radiohalogène
JP6284548B2 (ja) 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト抗タウ抗体
WO2014102399A1 (fr) 2012-12-31 2014-07-03 Neurimmune Holding Ag Anticorps humains recombinants destinés à la thérapie et à la prévention de maladies associées aux polyomavirus
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
HRP20191865T1 (hr) 2013-01-14 2020-01-10 Xencor, Inc. Novi heterodimerni proteini
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
WO2014113510A1 (fr) 2013-01-15 2014-07-24 Xencor, Inc. Elimination rapide de complexes antigéniques à l'aide de nouveaux anticorps
BR112015017560A2 (pt) * 2013-01-24 2018-05-15 Scripps Korea Antibody Institute biblioteca de fv à base de combinação de proteína e modo de preparação da mesma
AU2014214843A1 (en) 2013-02-07 2015-05-21 Immunomedics, Inc. Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
LT2956477T (lt) 2013-02-15 2021-02-10 Bioverativ Therapeutics Inc. Optimizuotas faktoriaus viii genas
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
BR112015022210A8 (pt) 2013-03-13 2018-01-23 Genentech Inc formulações de anticorpo
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
ES2882183T3 (es) 2013-03-14 2021-12-01 Univ Duke Moléculas biespecíficas que son inmunorreactivas con células efectoras inmunitarias que expresan un receptor activador
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
CA3093606A1 (fr) 2013-03-15 2014-09-18 Xencor, Inc. Proteines heterodimetriques pour l'induction de cellules t
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
MX368665B (es) 2013-03-15 2019-10-10 Abbvie Biotherapeutics Inc Variantes de fc.
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
HK1220918A1 (zh) 2013-04-19 2017-05-19 赛腾制药 降低的血管渗漏综合征的细胞因子衍生治疗
EP2805730A1 (fr) 2013-05-21 2014-11-26 Bergen Teknologioverforing AS Donneurs d'oxyde nitrique pour le traitement du syndrome de fatigue chronique
CA2913370C (fr) 2013-05-31 2022-12-13 Zymeworks Inc. Heteromultimeres a fonction effectrice reduite ou silencieuse
EP3013365B1 (fr) 2013-06-26 2019-06-05 Academia Sinica Antigènes rm2 et leur utilisation
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2840091A1 (fr) 2013-08-23 2015-02-25 MacroGenics, Inc. Diabody se liant specifiquement a l'antigene gpA33 et CD3 et procedes d'utilisation
EP2839842A1 (fr) 2013-08-23 2015-02-25 MacroGenics, Inc. Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations
WO2015035044A2 (fr) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Variants fc présentant une cytotoxicité cellulaire dépendante des anticorps améliorée
KR102298172B1 (ko) 2013-09-06 2021-09-06 아카데미아 시니카 변화된 글리코실 그룹을 갖는 당지질을 사용한 인간 iNKT 세포 활성화
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
EP3055298B1 (fr) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Acides aminés modifiés comprenant des groupes fonctionnels de tétrazine, procédés de préparation et procédés d'utilisation associés
WO2015063287A1 (fr) 2013-11-01 2015-05-07 Bergen Teknologioverføring As Activateurs ou stimulateurs de guanylate cyclase soluble destinés à être utilisés pour traiter un syndrome de fatigue chronique
JP6633520B2 (ja) 2013-11-12 2020-01-22 オージーディー２ ファーマ プロアポトーシス活性を有するヒトｉｇｇ１由来抗体
KR20160089532A (ko) 2013-12-17 2016-07-27 제넨테크, 인크. Pd-1 축 결합 길항제 및 항-cd20 항체를 사용하여 암을 치료하는 방법
KR20160104727A (ko) 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
EP2915569A1 (fr) 2014-03-03 2015-09-09 Cytune Pharma Procédé de purification de conjugués à base Il -15/IL-15Ralpha
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
TWI797430B (zh) 2014-03-27 2023-04-01 中央研究院 反應性標記化合物及其用途
EP3954713A3 (fr) 2014-03-28 2022-03-30 Xencor, Inc. Anticorps bispécifiques se liant à cd38 et cd3
US11400115B2 (en) 2014-04-23 2022-08-02 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
US20170049887A1 (en) 2014-04-25 2017-02-23 University Of Florida Research Foundation, Inc. Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20240096599A (ko) 2014-05-27 2024-06-26 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
US10005847B2 (en) 2014-05-27 2018-06-26 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
AU2015267052A1 (en) 2014-05-27 2016-12-15 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
CA2950926A1 (fr) 2014-06-13 2015-12-17 Mayo Foundation For Medical Education And Research Complexes de nanoparticules de paclitaxel liees a l'albumine/rituximab pour le traitement des lymphomes exprimant cd20
WO2015195476A1 (fr) 2014-06-16 2015-12-23 Mayo Foundation For Medical Education And Research Traitement de myélomes
EP3160478A4 (fr) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Gène du facteur ix optimisé
MX2017000231A (es) 2014-07-09 2017-06-27 Genentech Inc Ajuste del ph para mejorar la recuperacion por descongelamiento de bancos de celulas.
CN107074937B (zh) 2014-07-29 2021-07-27 神经免疫控股公司 人源抗亨廷顿蛋白(htt)抗体及其用途
CN107001404B (zh) 2014-09-08 2021-06-29 中央研究院 使用醣脂激活人类iNKT细胞
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
CN114181312A (zh) 2014-09-10 2022-03-15 豪夫迈·罗氏有限公司 半乳糖改造的免疫球蛋白1抗体
JP7072384B2 (ja) 2014-09-15 2022-05-20 ジェネンテック， インコーポレイテッド 抗体製剤
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
CN107108721B (zh) 2014-09-29 2021-09-07 杜克大学 包含hiv-1包膜靶向臂的双特异性分子
NZ729808A (en) 2014-09-30 2022-02-25 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
AU2015325055B2 (en) 2014-10-01 2021-02-25 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
SI3221359T1 (sl) 2014-11-17 2020-08-31 Regeneron Pharmaceuticals, Inc. Metode zravljenja tumorja z uporabo bispecifičnega protitelesa CD3XCD20
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CN116333153A (zh) 2014-11-26 2023-06-27 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
EP3223907A2 (fr) 2014-11-26 2017-10-04 Xencor, Inc. Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2016105450A2 (fr) 2014-12-22 2016-06-30 Xencor, Inc. Anticorps trispécifiques
AU2016205197B2 (en) 2015-01-08 2021-10-21 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
TWI736523B (zh) 2015-01-24 2021-08-21 中央研究院 新穎聚醣結合物及其使用方法
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
MX391249B (es) 2015-03-17 2025-03-21 Memorial Sloan Kettering Cancer Center Anticuerpos anti-muc16 y sus usos.
US10722523B2 (en) 2015-03-17 2020-07-28 The Regents Of The University Of California Chemoimmunotherapy for epithelial cancer
CN107592812A (zh) 2015-05-11 2018-01-16 豪夫迈·罗氏有限公司 治疗狼疮性肾炎的组合物和方法
MX2017015493A (es) 2015-05-30 2018-02-09 Molecular Templates Inc Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
EA201792623A1 (ru) 2015-06-03 2018-04-30 Бостон Биомедикал, Инк. Композиции, содержащие ингибитор стволовости рака и иммунотерапевтический агент, для применения в лечении рака
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
EP3108897A1 (fr) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Anticorps contre le csf-1r humain permettant d'induire une lymphocytose dans les lymphomes ou les leucémies
KR20180021864A (ko) 2015-06-29 2018-03-05 제넨테크, 인크. 장기 이식에서 사용하기 위한 유형 ii 항-cd20 항체
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
EP3334747B1 (fr) 2015-08-13 2023-09-27 Amgen Inc. Filtration en profondeur chargée de protéines de liaison à un antigène
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
WO2017053469A2 (fr) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Polypeptides de liaison à cd3
JP6657392B2 (ja) 2015-10-02 2020-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
US11472876B2 (en) 2015-11-02 2022-10-18 Bioatla, Inc. Conditionally active polypeptides
KR20180085800A (ko) 2015-12-07 2018-07-27 젠코어 인코포레이티드 Cd3 및 psma에 결합하는 이종이합체성 항체
US10525137B2 (en) 2015-12-30 2020-01-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
US11571469B2 (en) 2016-01-07 2023-02-07 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
PL3411478T3 (pl) 2016-02-01 2022-10-03 Bioverativ Therapeutics Inc. Geny zoptymalizowanego czynnika VIII
EP3413874A4 (fr) 2016-02-12 2020-01-22 Mayo Foundation for Medical Education and Research Traitements des cancers hématologiques
JP2019517991A (ja) 2016-03-01 2019-06-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 低減したａｄｃｐを有するオビヌツズマブ及びリツキシマブ変異体
EP3423593A1 (fr) 2016-03-02 2019-01-09 Institut National de la Sante et de la Recherche Medicale (INSERM) Procédés et kits de prédiction du risque de rechute chez des patients souffrant d'un syndrome néphrotique idiopathique
CA3016170A1 (fr) 2016-03-08 2017-09-14 Academia Sinica Procedes de synthese modulaire de n-glycanes et de puces a n-glycanes
UA125378C2 (uk) 2016-03-14 2022-03-02 Універшітетет І Осло МОДИФІКОВАНІ ІМУНОГЛОБУЛІНИ ЗІ ЗМІНЕНИМ ЗВ'ЯЗУВАННЯМ FcRn
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
AU2017238119A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
EP3432928A4 (fr) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research Procédés d'amélioration de l'indice thérapeutique d'un médicament chimiothérapeutique
KR20190012145A (ko) 2016-03-29 2019-02-08 젤터, 인코포레이티드 주변세포질 부피 대 세포질 부피의 비가 0.5:1 내지 10:1인 그람-음성 박테리아에서의 단백질의 발현
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
MY198114A (en) 2016-04-15 2023-08-04 Macrogenics Inc Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
WO2017182608A1 (fr) 2016-04-22 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions vaccinales pour le traitement des malignités des cellules b
AU2017268839A1 (en) 2016-05-27 2018-11-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat B-cell proliferative disorders
IL263542B2 (en) 2016-06-14 2024-10-01 Xencor Inc Bispecific antibodies inhibit immunological checkpoint
WO2017218698A1 (fr) 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Anticorps à domaines ch2 modifiés, compositions les contenant et leurs procédés d'utilisation
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
BR112019000630A2 (pt) 2016-07-13 2019-07-09 Biogen Ma Inc regimes de dosagem dos antagonistas de lingo-1 e usos para tratamento de distúrbios desmielinizante
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
GB201613167D0 (en) 2016-07-29 2016-09-14 Univ Southampton Cancer and b-cell related disease therapy
AU2017316663B2 (en) 2016-08-22 2024-02-22 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN107384932B (zh) 2016-08-31 2020-10-20 北京天广实生物技术股份有限公司 抗人cd20人源化单克隆抗体mil62、其制备方法及用途
JP2019526579A (ja) 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｔ細胞癌を標的とする為の方法及び組成物
MX2019002474A (es) 2016-09-01 2019-09-18 Mayo Found Medical Education & Res Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres.
RU2019110071A (ru) 2016-09-06 2020-10-08 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Способы лечения злокачественных новообразований, экспрессирующих pd-l1
WO2018048815A1 (fr) 2016-09-06 2018-03-15 Nantibodyfc, Llc Méthodes de traitement d'un cancer du sein triple-négatif à l'aide de compositions d'anticorps et de protéines porteuses
CN109890422A (zh) 2016-09-06 2019-06-14 梅约医学教育与研究基金会 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法
US20190247399A1 (en) 2016-09-09 2019-08-15 Tg Therapeutics, Inc. Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
CN108421048B (zh) * 2016-09-28 2021-04-20 首都医科大学附属北京世纪坛医院 纳米活性碳靶向药物递送系统、制备方法及其用途
IL265605B2 (en) 2016-09-29 2024-06-01 Beijing Hanmi Pharmaceutical Co Ltd Heterodimeric immunoglobulin constructs, pharmaceutical composition comprising the same, use and preparation methods thereof
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 免疫介在性療法薬を有する抗体−薬物コンジュゲート
CN110214148A (zh) 2016-10-14 2019-09-06 Xencor股份有限公司 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
AU2017364077A1 (en) 2016-11-22 2019-06-20 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
US20200003785A1 (en) 2016-12-01 2020-01-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of anti-uchl1 igg plasma concentration for diagnosing idiopathic steroid sensitive nephrotic syndrome
BR112019011198A2 (pt) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc métodos de indução de tolerância imune a fatores de coagulação
WO2018102743A1 (fr) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
EA201991768A1 (ru) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. Слитые белки на основе фактора ix и способы их получения и пути применения
CN108452319A (zh) 2017-02-20 2018-08-28 浙江特瑞思药业股份有限公司 靶向cd20的抗体偶联药物制剂
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
WO2018187074A1 (fr) 2017-04-03 2018-10-11 Immunomedics, Inc. Administration par voie sous-cutanée de conjugués anticorps-médicament à titre de thérapie anticancéreuse
EP3624846B1 (fr) 2017-05-16 2024-08-07 Bhami's Research Laboratory, Pvt. Ltd. Formulations de protéines à haute concentration ayant une viscosité réduite incluant une mixture d'acide nicotinique et tryoptophane
WO2018213424A1 (fr) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Méthodes pour le traitement du cancer
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
CN110945028B (zh) 2017-07-10 2023-09-08 国际药物发展生物技术公司 用非岩藻糖基化促凋亡抗cd19抗体与抗cd20抗体或化疗剂联合治疗b细胞恶性肿瘤
AU2018306303A1 (en) 2017-07-25 2020-02-20 Elektrofi, Inc. Formation of particles including agents
WO2019020606A1 (fr) 2017-07-26 2019-01-31 F. Hoffmann-La Roche Ag Polythérapie avec un inhibiteur bet, un inhibiteur bcl-2 et un anticorps anti-cd20
JP7374883B2 (ja) 2017-08-09 2023-11-07 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子およびその使用
US10759865B2 (en) 2017-08-22 2020-09-01 Eyal Levit Treatment of diabetes mellitus
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
WO2019077123A1 (fr) 2017-10-20 2019-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et kits pour identifier si un sujet est atteint ou risque d'être atteint d'une myopathie auto-immune
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3724327A4 (fr) 2017-12-14 2022-01-12 EZY Biotech LLC Cellules d'inhibition de tumeur spécifique à un sujet et leur utilisation
MX2020006322A (es) 2017-12-19 2020-09-18 Xencor Inc Proteinas de fusion il-2 fc modificadas.
MX2020009468A (es) 2018-03-13 2020-10-22 Hoffmann La Roche Terapias de combinacion de agonistas de 4-1bb con anticuerpos anti-cd20.
US11359000B2 (en) 2018-03-28 2022-06-14 Bristol-Myers Squibb Company Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
EP3781598A1 (fr) 2018-04-18 2021-02-24 Xencor, Inc. Protéines de fusion hétérodimères ciblant tim-3 contenant des protéines de fusion fc d'il-15/il-15ra et domaines de liaison à l'antigène de tim-3
CA3098128A1 (fr) 2018-04-18 2019-10-24 Ucl Business Ltd Lymphocyte t regulateur modifie
AU2019256539A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
JP2021521896A (ja) 2018-04-27 2021-08-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト由来の抗（ポリｇａ）ジペプチドリピート（ｄｐｒ）抗体
CA3098103A1 (fr) 2018-05-23 2019-11-28 Adc Therapeutics Sa Adjuvant moleculaire
US12115262B2 (en) 2018-05-24 2024-10-15 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
CA3104684A1 (fr) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Procedes de production de proteines recombinees
US12097199B2 (en) 2018-07-09 2024-09-24 Takeda Pharmaceutical Company Limited Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies
CN109273050B (zh) * 2018-08-03 2021-07-13 五邑大学 一种用于解析复杂多聚体蛋白受体的脉冲电子顺磁共振数据的系统及方法与应用
US20210186880A1 (en) 2018-08-03 2021-06-24 Brown University Oral formulations with increased uptake
CN119955796A (zh) 2018-08-09 2025-05-09 比奥维拉迪维治疗股份有限公司 核酸分子及其用于非病毒基因疗法的用途
RS66543B1 (sr) 2018-08-31 2025-03-31 Regeneron Pharma Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela
EP3847196A4 (fr) 2018-09-07 2023-01-04 ITabMed (HK) Limited Protéines de liaison à un antigène bispécifiques et leurs utilisations
CN112955172A (zh) 2018-09-17 2021-06-11 美国卫生和人力服务部 靶向cd19和cd20的双顺反子嵌合抗原受体及其用途
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
KR20210074341A (ko) 2018-10-10 2021-06-21 베링거 인겔하임 인터내셔날 게엠베하 고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
WO2020076849A1 (fr) 2018-10-11 2020-04-16 The Scripps Research Institute Composés d'anticorps avec arginine réactive et conjugués anticorps-médicament associés
US20210388101A1 (en) 2018-10-15 2021-12-16 Industry-Academic Cooperation Foundation, Yonsei University Productivity-enhanced antibody and method for producing same
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
US20210403971A1 (en) 2018-11-02 2021-12-30 Kyowa Kirin Co., Ltd. Method for preparing liquid medium
US20220016277A1 (en) 2018-11-20 2022-01-20 Cornell University Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
KR20210100668A (ko) 2018-12-06 2021-08-17 제넨테크, 인크. 항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
EP3891270A1 (fr) 2018-12-07 2021-10-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Utilisation de cd26 et cd39 en tant que nouveaux marqueurs phénotypiques pour évaluer la maturation de lymphocytes t ffoxp3+ et leurs utilisations à des fins de diagnostic
AU2020214626B2 (en) 2019-01-31 2025-10-16 Elektrofi, Inc. Particle formation and morphology
CN113795513B (zh) 2019-02-13 2025-02-18 布里格姆妇女医院 抗外周淋巴结地址素抗体及其用途
CN113728107B (zh) 2019-02-18 2022-06-24 Atb治疗公司 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法
WO2020176748A1 (fr) 2019-02-27 2020-09-03 Genentech, Inc. Dosage pour traitement avec des anticorps anti-tigit et anti-cd20 ou anti-cd38
AU2020232605A1 (en) 2019-03-01 2021-10-21 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
KR20210145152A (ko) 2019-04-01 2021-12-01 제넨테크, 인크. 단백질-함유 제제들의 안정화를 위한 조성물들 및 방법들
JP7777451B2 (ja) 2019-04-12 2025-11-28 ジェルター， インコーポレイテッド 組換えエラスチンおよびその産生
JP7550794B2 (ja) 2019-05-14 2024-09-13 ジェネンテック， インコーポレイテッド 濾胞性リンパ腫を処置するための抗ｃｄ７９ｂ免疫複合体の使用方法
CN114269749B (zh) 2019-06-10 2024-10-01 苏特罗生物制药公司 5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物
US20220259202A1 (en) 2019-06-17 2022-08-18 Sutro Biopharma, Inc. 1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
US20220315887A1 (en) 2019-08-01 2022-10-06 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
EP4021457A1 (fr) 2019-08-30 2022-07-06 Vestlandets Innovasjonsselskap AS Procédé de traitement du syndrome de fatigue chronique à l'aide d'un agent inhibiteur ou cytotoxique contre des cellules plasmatiques
EP4438057A3 (fr) 2019-09-12 2025-01-01 F. Hoffmann-La Roche AG Compositions et méthodes de traitement de la néphropathie lupique
JP7781743B2 (ja) 2019-09-13 2025-12-08 エレクトロフィ，インコーポレイテッド 疾患の処置のための治療用生物学的作用剤の送達のための組成物及び方法
CN115279896A (zh) 2019-09-30 2022-11-01 比奥维拉迪维治疗股份有限公司 慢病毒载体配制品
CR20220166A (es) 2019-10-18 2022-06-15 Genentech Inc Métodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes
AU2019474716A1 (en) 2019-11-19 2022-07-07 Protalix Ltd. Removal of constructs from transformed cells
JP2023512084A (ja) 2020-01-31 2023-03-23 シージェン インコーポレイテッド 抗ｃｄ３０抗体薬物コンジュゲート及び非ホジキンリンパ腫の治療のためのその使用
WO2021168271A1 (fr) 2020-02-19 2021-08-26 Elektrofi, Inc. Formation de gouttelettes et morphologie de particules
AU2021228778A1 (en) 2020-02-28 2022-09-22 The Brigham And Women's Hospital, Inc. Selective modulation of transforming growth factor beta superfamily signaling via multi-specific antibodies
EP4114852A1 (fr) 2020-03-03 2023-01-11 Sutro Biopharma, Inc. Anticorps comprenant des étiquettes de glutamine spécifiques à un site, leurs procédés de préparation et d'utilisation
JP2023522627A (ja) 2020-04-17 2023-05-31 エレクトロフィ，インコーポレイテッド 連続的な液滴形成及び脱水によって粒子を形成する方法
CN115916822A (zh) 2020-04-24 2023-04-04 基因泰克公司 使用抗CD79b免疫缀合物的方法
EP4143234A4 (fr) 2020-04-26 2024-07-17 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Immunoglobulines modifiées
JP7560575B2 (ja) 2020-05-03 2024-10-02 シャンハイ ミラコーケン インコーポレイティド 抗体－薬物コンジュゲート及びその調製物
US20230227570A1 (en) 2020-05-08 2023-07-20 Genmab A/S Bispecific antibodies against cd3 and cd20
WO2021231976A1 (fr) 2020-05-14 2021-11-18 Xencor, Inc. Anticorps hétérodimères qui se lient à l'antigène membranaire spécifique de la prostate (psma) et cd3
GB202007842D0 (en) 2020-05-26 2020-07-08 Quell Therapeutics Ltd Polypeptide useful in adoptive cell therapy
MX2023000156A (es) 2020-06-24 2023-02-16 Bioverativ Therapeutics Inc Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina.
EP4189121A1 (fr) 2020-08-03 2023-06-07 Genentech, Inc. Méthodes diagnostiques et thérapeutiques pour le lymphome
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
CN112062855B (zh) 2020-08-26 2024-08-30 北京天诺健成医药科技有限公司 一种含有衔接器的药物治疗剂的开发和应用
WO2022043415A1 (fr) 2020-08-27 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de détection de la présence d'auto-anticorps spécifiques à un pemphigus dans un échantillon
GB202013477D0 (en) 2020-08-27 2020-10-14 Quell Therapeutics Ltd Nucleic acid constructs for expressing polypeptides in cells
CN116406293A (zh) 2020-09-10 2023-07-07 健玛保 用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
JP2023541860A (ja) 2020-09-10 2023-10-04 ジェンマブ エー／エス びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
CA3190376A1 (fr) 2020-09-10 2022-03-17 Brian Elliott Anticorps bispecifique contre cd3 et cd20 en polytherapie pour le traitement d'un lymphome folliculaire
CA3190349A1 (fr) 2020-09-10 2022-03-17 Brian Elliott Anticorps bispecifiques contre cd3 et cd20 de traitement de la leucemie lymphoide chronique
BR112023004296A2 (pt) 2020-09-10 2023-04-04 Genmab As Método para tratar linfoma de célula b grande difusa em um indivíduo humano
WO2022066595A1 (fr) 2020-09-22 2022-03-31 Bristol-Myers Squibb Company Procédés de production de protéines thérapeutiques
EP4225902A1 (fr) 2020-10-05 2023-08-16 Protalix Ltd. Cellules végétales inactivées de type dicer
WO2022079211A1 (fr) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugués
WO2022103983A2 (fr) 2020-11-11 2022-05-19 Sutro Biopharma, Inc. Composés de fluorénylméthyloxycarbonyle et de fluorénylméthylaminocarbonyle, conjugués protéines associés et méthodes d'utilisation
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
MX2023010812A (es) 2021-03-15 2023-09-27 Genentech Inc Composiciones y metodos para tratar la nefritis lupica.
WO2022204282A1 (fr) 2021-03-24 2022-09-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Récepteurs antigéniques chimériques bicistroniques conçus pour réduire la recombinaison rétrovirale et leurs utilisations
JPWO2022224980A1 (fr) 2021-04-20 2022-10-27
US20240262917A1 (en) 2021-05-06 2024-08-08 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
MX2023013264A (es) 2021-05-12 2023-11-30 Genentech Inc Metodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes.
WO2022253756A1 (fr) 2021-06-01 2022-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'agents de déplétion de lymphocytes b pour le traitement d'une cardiopathie rhumatismale
EP4352096A1 (fr) 2021-06-08 2024-04-17 Xyphos Biosciences Inc. Protéine de fusion de domaine ligand nkg2d-anticorps
PH12023553282A1 (en) 2021-06-08 2024-04-29 Xyphos Biosciences Inc Antibody-nkg2d ligand domain fusion protein
KR20240021959A (ko) 2021-06-17 2024-02-19 펫메딕스 리미티드 항개 cd20 항체
CA3220318A1 (fr) 2021-06-17 2022-12-22 Glaxosmithkline Intellectual Property Limited Anticorps anti-baff destines a etre utilises dans une methode de traitement d'une infection par sars-cov-2 a sequelles de covid prolongees et/ou post-aigues (pasc)
WO2023010060A2 (fr) 2021-07-27 2023-02-02 Novab, Inc. Anticorps anti-vlrb génétiquement modifiés présentant des fonctions effectrices immunitaires
WO2023015234A1 (fr) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Procédés de culture cellulaire pour la production de protéines thérapeutiques
EP4380974A1 (fr) 2021-08-06 2024-06-12 Petmedix Ltd. Variants de fc d'anticorps
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
EP4392443A1 (fr) 2021-08-23 2024-07-03 Bioverativ Therapeutics Inc. Gènes de facteur viii optimisés
IL310963A (en) 2021-08-23 2024-04-01 Bioverativ Therapeutics Inc Production of closed DNA with inverted repeat sequences
US20240390869A1 (en) 2021-09-21 2024-11-28 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
CA3232988A1 (fr) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Acides nucleiques codant pour des polypeptides du facteur viii a immunogenicite reduite
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
CA3236930A1 (fr) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Conjugaison specifique d'un anticorps
AU2022396272A1 (en) 2021-11-24 2024-06-06 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
CA3241395A1 (fr) 2021-12-17 2023-06-22 Barbel SCHROFELBAUER Anticorps et leurs utilisations
US20250051755A1 (en) 2021-12-17 2025-02-13 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
US20230303693A1 (en) 2022-01-28 2023-09-28 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CN119212728A (zh) 2022-02-04 2024-12-27 丹娜-法伯癌症研究院 用于处理神经病的组合物和方法
EP4476256A1 (fr) 2022-02-09 2024-12-18 Petmedix Ltd. Anticorps thérapeutiques
WO2023164487A1 (fr) 2022-02-22 2023-08-31 Brown University Compositions et procédés pour obtenir une absorption systémique de particules suite à une administration par voie orale ou muqueuse
CN118974091A (zh) 2022-04-11 2024-11-15 阿斯利康(瑞典)有限公司 T细胞结合蛋白
JP2025515474A (ja) 2022-04-29 2025-05-15 エレクトロフィ，インコーポレイテッド 注射可能な懸濁液
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
WO2024006272A1 (fr) 2022-06-27 2024-01-04 Sutro Biopharma, Inc. CHARGES UTILES DE LIEUR β-GLUCURONIDE, LEURS CONJUGUÉS PROTÉIQUES ET MÉTHODES ASSOCIÉES
JP2025523752A (ja) 2022-07-15 2025-07-25 ストロ バイオファーマ インコーポレーテッド プロテアーゼ／酵素切断可能リンカー－ペイロードおよびタンパク質コンジュゲート
WO2024039670A1 (fr) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Anticorps anti-cldn4 et leurs méthodes d'utilisation
JP2025528835A (ja) 2022-08-15 2025-09-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｓｌｎに対する抗体及びその使用方法
AU2023375342A1 (en) 2022-11-08 2025-04-24 F. Hoffmann-La Roche Ag Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
WO2024153636A1 (fr) 2023-01-17 2024-07-25 Institut National de la Santé et de la Recherche Médicale Vasorine en tant que biomarqueur et biocible en néphrologie
WO2024182516A1 (fr) 2023-02-28 2024-09-06 Juno Therapeutics, Inc. Thérapie cellulaire pour le traitement de maladies auto-immunes systémiques
AU2024283865A1 (en) 2023-06-08 2025-11-27 Genentech, Inc. Macrophage signatures for diagnostic and therapeutic methods for lymphoma
WO2025021782A1 (fr) 2023-07-24 2025-01-30 Institut National de la Santé et de la Recherche Médicale Procédés pour déterminer si un sujet souffrant de néphrite lupique (ln) est sensible à une thérapie par induction
WO2025029832A2 (fr) 2023-07-31 2025-02-06 Sutro Biopharma, Inc. Composés agonistes de sting et conjugués
WO2025045894A1 (fr) 2023-08-28 2025-03-06 Institut National de la Santé et de la Recherche Médicale Méthodes et trousses de diagnostic de cause du syndrome néphrotique et d'orientation de la thérapie
WO2025054552A1 (fr) 2023-09-08 2025-03-13 Elektrofi, Inc. Particules et suspensions comprenant des agents de dégradation d'hyaluronane et leurs procédés d'utilisation
TW202532433A (zh) 2023-10-10 2025-08-16 瑞典商阿斯特捷利康公司 Ｔ細胞結合組成物和方法
WO2025080711A1 (fr) 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Conjugués médicament-anticorps à double charge utile
TW202528347A (zh) 2023-11-15 2025-07-16 瑞士商紐立慕公司 抗運甲狀腺素蛋白抗體、包含所述抗體之組成物及用於治療或預防運甲狀腺素蛋白介導之澱粉樣變性的方法
US20250179207A1 (en) 2023-11-30 2025-06-05 Genzyme Corporation Methods for treating digitally-identified cd20-related disorders
WO2025226808A1 (fr) 2024-04-24 2025-10-30 Genentech, Inc. Compositions et méthodes de traitement de la néphrite lupique

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US206903A (en) * 1878-08-13 Improvement in cultivators
US147885A (en) * 1874-02-24 Improvement in the manufacture of halters and bridles
US213784A (en) * 1879-04-01 Improvement in inlaying metallic scroll-ornaments in hard rubber and allied gums
US26804A (en) * 1860-01-10 Bridle-bit
US21781A (en) * 1858-10-12 Improved method o f lighting street-lamps by electricity
US9444A (en) * 1852-12-07 Hot-air furnace
US197255A (en) * 1877-11-20 Improvement in receivers and stench-traps for street-sewers
US95963A (en) * 1869-10-19 Improvement in fence
US186205A (en) * 1877-01-16 Improvement in buffing-rolls for thesoles of boots andshoes
US163708A (en) * 1875-05-25 Improvement in harvester-rakes
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (fr) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
USRE38008E1 (en) * 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5439665A (en) * 1988-07-29 1995-08-08 Immunomedics Detection and treatment of infectious and inflammatory lesions
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH06501705A (ja) * 1990-11-05 1994-02-24 ブリストル−マイアーズ　スクイブ　カンパニー 抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5686072A (en) * 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
ES2091684T3 (es) * 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5648267A (en) * 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5678180A (en) * 1995-06-07 1997-10-14 Hughes Electronics Communication system and method providing dispatch and cellular interconnect communications
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies

Also Published As

Publication number Publication date
ES2326144T3 (es) 2009-10-01
US5736137A (en) 1998-04-07
MY111196A (en) 1999-09-30
GEP20074162B (en) 2007-07-10
CN1094965A (zh) 1994-11-16
HK1125574A1 (en) 2009-08-14
SG45294A1 (en) 1998-01-16
HU9501410D0 (en) 1995-06-28
GEPI20105119B (en) 2010-11-25
EP2000149B1 (fr) 2009-05-13
LU91620I2 (fr) 2010-01-11
DE69334285D1 (de) 2009-06-25
HUT72914A (en) 1996-06-28
CN1607006A (zh) 2005-04-20
TW376320B (en) 1999-12-11
ATE421335T1 (de) 2009-02-15
CN1912111B (zh) 2010-05-26
IL107591A (en) 2000-02-17
HK1109633A1 (en) 2008-06-13
HU219264B (en) 2001-03-28
IL107591A0 (en) 1994-02-27
CN1607006B (zh) 2012-09-19
GEP20105119B (en) 2010-11-25
DE122009000070I1 (de) 2010-02-11
CN1912111A (zh) 2007-02-14
DE69334259D1 (de) 2009-03-12
ES2321567T3 (es) 2009-06-08
PT2000149E (pt) 2009-07-14
CN101007851A (zh) 2007-08-01
KR100365632B1 (ko) 2003-08-02
HK1109634A1 (en) 2008-06-13
CN101007850A (zh) 2007-08-01
CN101007851B (zh) 2012-09-12
US20030082172A1 (en) 2003-05-01
CN101007850B (zh) 2012-05-30
PT1005870E (pt) 2009-04-28
NL300424I1 (nl) 2010-01-04
EP2000149A1 (fr) 2008-12-10
ATE431158T1 (de) 2009-05-15
DK1005870T3 (da) 2009-05-18
FR04C0018I1 (fr) 2008-09-26
CA2626445A1 (fr) 1994-05-26
UA27946C2 (uk) 2000-10-16
PL175557B1 (pl) 1999-01-29
ZA938466B (en) 1994-06-20
BR1100622A (pt) 2000-04-18
CN1270774C (zh) 2006-08-23
DK2000149T3 (da) 2009-08-03

Similar Documents

Publication Publication Date Title
FR04C0018I2 (fr)
LU91089I2 (fr) Ibritumomab.
TW224942B (fr)
EP0469782A3 (en) Treatment of cataract with prostacyclin compounds